Surgery for recurrent ovarian cancer after chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of secondary interval cytoreductive surgery in patients with recurrent epithelial ovarian cancer who have responded to platinum-based chemotherapy. It aims to determine the rate of complete tumor resection and assess the safety and survival outcomes associated with this surgical approach. The study involves administering chemotherapy agents such as carboplatin, paclitaxel, and bevacizumab, followed by surgical intervention for eligible patients. The goal is to improve treatment outcomes for those with recurrent ovarian cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma
* \>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting
* Platinum-free interval should be \>=6 months from the last dose of platinum-based chemotherapy
* Upfront SCR not feasible
* Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment.
* Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment.

Exclusion Criteria:

* Non-epithelial or borderline tumors are excluded
* Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded.
* Patients using more than one line of chemotherapy are excluded.
* Patients who have platinum-resistant or refractory recurrence are excluded.
* Patients having second relapse or beyond are excluded.
* Patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment

Where it's running

• The University of Hong Kong
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Ka Yu Tse — The University of Hong Kong
• Study coordinator: Lesley Lau
• Email: lsk382@hku.hk
• Phone: 852-22554265

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Probiotic support for gut and vaginal microbiome during platinum chemotherapy for advanced or recurrent ovarian cancer

  This trial will test whether taking a probiotic during platinum chemotherapy helps keep the gut and vaginal microbiome healthier and may improve symptoms, quality of life, or cancer outcomes for people with advanced or recurrent ovarian cancer.

  Recruiting Early Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07144826

• Automated physical activity program for cancer patients

  This study is testing whether a personalized exercise program using wearable technology can help cancer patients be more active compared to regular exercise advice.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT06855706

• Using MUC1-activated T cells to treat resistant ovarian cancer

  This study is testing a new treatment using specially designed immune cells to see if they can help people with tough-to-treat ovarian cancer feel better and improve their health.

  Recruiting Phase 1 Mayo Clinic · Scottsdale, Arizona · NCT06483048

• Investigating blood cancer risks in patients with ovarian and other solid tumors

  This study is trying to see if certain cancer treatments for ovarian and other solid tumors can increase the risk of blood cancers in patients.

  Recruiting University of Washington · Seattle, Washington · NCT06295965

• Targeted therapy for advanced solid tumors based on genetic testing

  This study is testing whether matching patients with advanced solid tumors to specific treatments based on their genetic makeup can improve their outcomes when standard options have failed.

  Recruiting at 437 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 483 other locations · NCT05564377

• Combining pembrolizumab and bevacizumab with an immune booster for recurrent ovarian cancer

  This study is testing a new combination of two cancer drugs, pembrolizumab and bevacizumab, with or without an immune booster, to see if it helps people with recurrent ovarian cancer feel better and live longer.

  Recruiting at 2 sites Phase 2 Roswell Park Cancer Institute · Buffalo, New York and 1 other locations · NCT05231122

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.